We use cookies necessary to giving you a better online experience. By using our website you consent to all cookies in accordance with our Privacy Policy.
Yes, I accept
Menu
Search Opener
Vienna, Austria

ESTRO 2023

Session Item

Upper GI
6010
Poster (Digital)
Clinical
Chemoradiation versus chemotherapy alone in locally advanced biliary cancer. A meta-analysis.
Silvia Cammelli, Italy
PO-1346

Abstract

Chemoradiation versus chemotherapy alone in locally advanced biliary cancer. A meta-analysis.
Authors:

Silvia Bisello1, Claudio Malizia2, Anna Benini3, Filippo Mammini3, Viola Laghi3, Silvia Paolinelli3, Alessandra Guido4, Andrea Galuppi4, Alessandra Arcelli5, Martina Ferioli1, Milly Buwenge3, Gabriella Macchia6, Fracesco Deodato6, Savino Cilla7, Silvia Cammelli8, Alessio Giuseppe Morganti1

1Radiation Oncology, Department of Experimental, Diagnostic and Specialty Medicine-DIMES, Alma Mater Studiorum University of Bologna, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; 2Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, , Bologna, Italy; 3Radiation Oncology, Department of Experimental, Diagnostic and Specialty Medicine-DIMES , Alma Mater Studiorum University of Bologna, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; 4Radiation Oncology , IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; 5Radiation Oncology , IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; 6Radiation Oncology Unit , Gemelli Molise Hospital-Università Cattolica del Sacro Cuore, Campobasso, Italy; 7Medical Physics Unit, Gemelli Molise Hospital-Università Cattolica del Sacro Cuore, Campobasso , Italy; 8Radiation Oncology, Department of Experimental, Diagnostic and Specialty Medicine-DIMES , Alma Mater Studiorum University of Bologna, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy

Show Affiliations
Purpose or Objective

Biliary tract cancers (BTC) are rare and aggressive neoplasms. Based on international guidelines the standard treatment of locally advanced or unresectable BTC is chemotherapy (CHT) alone.  Chemoradiation (CRT) may represent an alternative treatment. Aim of this study is to analyse the available comparisons between combined CRT or CHT alone for primary or recurrent unresectable BTC.


Material and Methods

Papers were searched on PubMed, Scopus, and Cochrane Library. Prospective or retrospective trials reporting a comparison between concurrent CRT or CHT alone for unresectable non-metastatic, primary or recurrent BTC were included. Only English-written papers, published from January 2010 to June 2022 were considered.


Results

Four papers were included in the analysis, with a total of 1578 patients with locally advanced BTC treated with concurrent CRT, and 4521 treated with CHT alone. Three studies included only patients with intrahepatic BTC, while one series included only patients with gallbladder cancer.
Median follow up was 10.1 months (range 9.0-11.3 months). Median overall survival for CRT group was 12.9 months (range 12.7-13.6) and 10.5 months (range 7.8 – 12.0) in patients treated with CRT ad CHT, respectively.  The meta-analysis showed a significant advantage in favour of CRT (HR 0.70, 0.59-0.82, 95% CI;  p<0.001).




Conclusion

This meta-analysis shows a significant advantage of concurrent CRT, in terms of OS, compared to CHT alone.